Assessment of the Immunogenicity and Protective Aspects of a DNA Vaccine Targeting Crimean Congo Hemorrhagic Fever Virus Glycoprotein Gc

Basit Öğe Kaydı
dc.contributor.authorÖzkul, Aykut
dc.contributor.authorFarzani, Touraj Aligholipour
dc.contributor.authorŞahin, Ergin
dc.contributor.authorCihan, Arzu Çöleri
dc.contributor.authorEngin, Evren Doruk
dc.contributor.authorFöldes, Katalin
dc.date.accessioned2023-04-10T20:19:35Z
dc.date.available2023-04-10T20:19:35Z
dc.date.issued2021
dc.departmentRektörlük, Rektörlüğe Bağlı Birimler, Düzce Üniversitesi Dergilerien_US
dc.description.abstractAim: Crimean Congo Hemorrhagic Fever (CCHF) is a lethal, endemic infectious disease inhuman. For the preventive measures of the disease, there is currently no safe and efficient vaccine,widely for human use. Vaccine development for CCHF virus is an actively researched subject. Inthis study, we aimed to investigate the immunizing and protective potentials of the CCHF virussurface glycoprotein Gc that is delivered as a single antigen via a DNA based vaccine vector.Material and Methods: A DNA based vaccine targeting the immunogenic envelope glycoproteinGc of a CCHF virus isolate with Turkey origin (Ank2) was generated and its immunogenicity andprotective capability against lethal challenge in IFN?/?R-/- receptor knock out mice was assessed.Results: The developed vaccine candidate (pGc) elicited a considerable amount of neutralizingantibody responses in the vaccinated mice. The vaccine candidate significantly induced bothantiviral Th1 and B cell activating Th2 immune responses deduced from the cytokineproduction profiles in the vaccinated mice. However, despite the immune responses elicitedpost-immunization, the vaccine failed to confer protection against lethal CCHF virus infection.Conclusion: To the best of our knowledge, this is the first report of a DNA vaccine candidategenerated against CCHF virus based on the glycoprotein Gc. The pGc vaccine candidate exhibitedantigen-specific immunity in IFN/?/?R-/- mice, but was unable to produce a protection upon lethalchallenge with the homologous CCHF virus. Once we comprehensively understand the immunecorrelates of protection, we will be more eligible to significantly improve the efficacy of vaccines.en_US
dc.identifier.doi10.18678/dtfd.864114
dc.identifier.endpage75en_US
dc.identifier.issn1307-671X
dc.identifier.issue1en_US
dc.identifier.startpage66en_US
dc.identifier.trdizinid421878en_US
dc.identifier.urihttp://doi.org/10.18678/dtfd.864114
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/421878
dc.identifier.urihttps://hdl.handle.net/20.500.12684/11423
dc.identifier.volume23en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofDüzce Tıp Fakültesi Dergisi
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleAssessment of the Immunogenicity and Protective Aspects of a DNA Vaccine Targeting Crimean Congo Hemorrhagic Fever Virus Glycoprotein Gcen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
11423.pdf
Boyut:
968.27 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Düzce Tıp Fakültesi Dergisi Koleksiyonu